Information Provided By: 
Fly News Breaks for May 15, 2015
REGN
May 15, 2015 | 08:15 EDT
Credit Suisse analyst Jeremiah Shepard said that Regeneron's multiple pipeline programs, the potential for its discovery engine to create an "unparalleled" number of new targets and its ability to leverage new drug combinations with Eylea to answer competitive threats in the eye disease space give the company strong growth potential despite its $50B market capitalization. Shepard increased the value attributed to Regeneron's Eylea franchise and pipeline and raised his price target on the Outperform rated shares to $550 from $400.
News For REGN From the Last 2 Days
There are no results for your query REGN
